CYLERT
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jan 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYLERT is an oral tablet approved in 1975 as a non-biologic new drug application (NDA) sponsored by Abbott. The mechanism of action and specific indications are not documented in available data. This is a legacy small-molecule product approaching loss of exclusivity.
LOE Approaching
Product facing imminent loss of exclusivity with low job attachment (0 linked roles), indicating a legacy brand with minimal active team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring on CYLERT; this is a managed legacy asset rather than a growth driver. Career development on this product is limited; professionals should evaluate it as a maintenance role with lower visibility and advancement potential.
Brand ManagerField Sales
Worked on CYLERT at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.